Mckesson Third Party Logistics Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Mckesson Third Party Logistics Pharmaceutical Import Records from India — 2 Products, $550.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mckesson Third Party Logistics — Pharmaceutical Importer Profile (2026) | 2 Products, $550.0K Trade | TransData Nexus

Mckesson Third Party Logistics

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $550.0K Total Trade · DGFT Verified

Mckesson Third Party Logistics is a pharmaceutical importer based in United States with a total trade value of $550.0K across 2 products in 2 therapeutic categories. Based on 11 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mckesson Third Party Logistics sources from 4 verified Indian suppliers, with Ajanta Pharma Limited accounting for 63.8% of imports.

Mckesson Third Party Logistics — Import Portfolio & Supplier Network

Mckesson Third Party Logistics import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mckesson Third Party Logistics?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ajanta Pharma Limited	$5.7M	287	63.8%
Encube Ethicals Private Limited	$2.6M	61	28.7%
Aurobindo Pharma Limited

What Formulations Does Mckesson Third Party Logistics Import?

Formulation	Value	Ships
Cefpodoxime proxetil tablets 200MG cefpodoxime proxetil tablets USP 200 MG	$300.0K	6
Testosterone gel 1.62% - 88g b.no 4lp18,4lp17,4lp14,4lp15,4lp19 mfg date dec 2024 exp date nov	$100.0K	2
Testosterone gel 1.62% - 88g b.no 4lp20to,4lp24, mfg date dec 2024 exp date nov	$100.0K	2
Testosterone gel 1.62% - 88g b.no.5lp02,5lp05,5lp07,5lp04,5lp03,5lp01,5lp06 mfgdt.jan 2025 exp dt.dec 2026 b no.4lp25	$100.0K	2
Testosterone gel 1.62% - 88g b.no.5lp10,5lp08,5lp09 mfg dt.jan 2025 exp dt.dec 2026 b no.5lp14,5lp11,5lp13,5lp12 mfg dt.	$100.0K	2
Tavaborole topical solution,5% 10 ML b.no.5bx31,5bx26,5bx32,5bx30,5bx39,5bx38,5bx365bx33,5bx34,5bx37,5bx35,5bx28,5bx27	$100.0K	2
Ciclopirox solution topical 8% 6.6ML(batch no 5ju21,5ju16,5ju18,5ju22,5ju20,5ju19 mfg. dt.mar 2025 exp. dt feb 2027)	$100.0K	2
Duloxetine delayed release capsules 20MG[118080pacx1x60=7084800 capsules]Each hard gelatin capsule cont.as per	$100.0K	2
Clonidine hydrochloride er tablets 0.1MG[34,488 x 1 x 60 = 2,069,280 tablets] cont as per	$100.0K	2
Entacapone tablets 200MG [34,512 x 1 x 100 = 3451200 tablets] Each film coated tablet contains: entacapone	$100.0K	2
Duloxetine delayed release capsules 20MG 7074x1x1000 7074000 capsules Each hard gelatin capsules cont as per	$100.0K	2
Clonidine hydrochloride er tablets 0 1MG 70800x1x60 4248000 tabs Each extendedrelease tablets cont as per	$100.0K	2
Tadalafil tablets USP 5MG 13200pacx1x500 6600000 tablets Each film coated tabletcontains tadalafil USP 5MG	$100.0K	2
Duloxetine delayed release capsules 30MG 9966pacx1x1000 9966000 capsules Each hard gelatin capsule cont as per	$100.0K	2
Clindamycin hydrochloride capsules USP	$97.3K	2

Mckesson Third Party Logistics imports 278 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cefpodoxime	Advanced Antibiotics	$400.0K	8	0.5%	5
2	Fluorouracil	Oncology	$150.0K	3	1.2%	17

Mckesson Third Party Logistics imports 2 pharmaceutical products across 2 categories into United States totaling $550.0K.

Mckesson Third Party Logistics — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

McKesson Third Party Logistics (3PL) is a specialized division within McKesson Corporation, a leading healthcare services and pharmaceutical distribution company headquartered in Louisville, Kentucky, USA. McKesson Corporation operates through various segments, including U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.

As a third-party logistics provider, McKesson 3PL focuses on the secure and efficient distribution of pharmaceutical products, including complex therapies such as cell and gene treatments, frozen plasma, and high-volume generic drugs. Their services are designed to support biopharmaceutical companies by managing the intricacies of the supply chain, thereby allowing these companies to concentrate on innovation and patient care.

In the United States pharmaceutical distribution landscape, McKesson 3PL plays a pivotal role as a logistics intermediary. By leveraging McKesson Corporation's extensive infrastructure and expertise, McKesson 3PL ensures that pharmaceutical products reach their intended destinations safely and promptly, thereby enhancing the overall efficiency and reliability of the healthcare supply chain.

2Distribution Network

McKesson 3PL operates an extensive distribution network across the United States, encompassing over 1.5 million square feet of warehouse space. This expansive infrastructure enables them to manage a diverse range of pharmaceutical products, including ambient, refrigerated, frozen, and controlled substances. Their logistics capabilities are tailored to meet the specific needs of various therapies, ensuring compliance with stringent regulatory standards and maintaining product integrity throughout the distribution process.

While the primary focus of McKesson 3PL is on the U.S. market, their parent company, McKesson Corporation, has a global presence, which may facilitate international distribution. However, specific details regarding McKesson 3PL's operations beyond the United States are not readily available.

3Industry Role

Within the United States pharmaceutical supply chain, McKesson 3PL serves as a logistics intermediary. Their role involves managing the distribution of pharmaceutical products from manufacturers to various stakeholders, including wholesalers, pharmacies, hospitals, and other healthcare providers. By handling the complexities of logistics, McKesson 3PL ensures that pharmaceutical products are delivered efficiently and in compliance with regulatory requirements, thereby supporting the broader healthcare system in delivering timely and safe patient care.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mckesson Third Party Logistics

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

McKesson 3PL's sourcing strategy exhibits a significant concentration, with a total import value of $550,000 USD from India across 11 shipments, focusing on two products: Cefpodoxime and Fluorouracil. This concentration indicates a strategic choice to source specific pharmaceutical formulations from India, likely due to factors such as cost-effectiveness, quality, and reliability.

The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import volumes over the period. This stability suggests that McKesson 3PL has established reliable partnerships with these suppliers, ensuring a steady supply of the required products. However, the lack of diversification in sourcing could pose risks related to supply chain disruptions, currency fluctuations, or changes in regulatory policies affecting imports from India.

2Supply Chain Resilience

McKesson 3PL's supply chain resilience concerning Indian imports appears robust, given the consistent import volumes and established relationships with suppliers. The diversity of formulations imported—278 unique formulations—indicates a broad sourcing strategy that can mitigate risks associated with dependency on a limited number of products.

However, the concentration on two specific products suggests that McKesson 3PL may be vulnerable to supply chain disruptions affecting these items. To enhance resilience, it would be prudent for McKesson 3PL to consider diversifying its supplier base and exploring alternative sourcing options. Additionally, evaluating the regulatory compliance status of key suppliers and assessing the stability of shipping routes can further strengthen the supply chain's resilience.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and distribution of pharmaceutical products. The FDA ensures that imported drugs meet the necessary safety, efficacy, and quality standards before they can be marketed and distributed within the U.S.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Enforcement Administration (DEA) regulations for controlled substances. These laws establish the framework for the approval process, labeling requirements, and compliance standards for imported pharmaceuticals.

For Indian generics to enter the U.S. market, they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This pathway ensures that generic drugs are therapeutically equivalent to their branded counterparts, maintaining the integrity of patient care.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent. Importers must register with the FDA and comply with the agency's regulations concerning the importation of drugs. This includes ensuring that imported products are manufactured in facilities that adhere to Good Manufacturing Practice (GMP) standards recognized by the FDA.

Mckesson Third Party Logistics — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

McKesson 3PL's focus on importing advanced antibiotics and oncology products aligns with the growing demand for specialized therapies in the U.S. market. Advanced antibiotics are crucial in combating resistant infections, while oncology treatments are essential due to the rising incidence of cancer. By sourcing these products from India, McKesson 3PL can leverage cost-effective manufacturing and a diverse range of formulations to meet market needs.

The importation of these specific therapeutic areas is driven by market demand for effective treatments and the need to address public health challenges. McKesson 3PL's strategic sourcing ensures a steady supply of these critical medications, supporting healthcare providers in delivering optimal patient care.

2Sourcing Profile

McKesson 3PL's sourcing strategy emphasizes the procurement of generic drugs, particularly in the advanced antibiotics and oncology categories. This focus allows them to offer cost-effective alternatives to branded medications, thereby enhancing accessibility for patients. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a preferred sourcing destination for these products.

The diversity of formulations imported—278 unique formulations—indicates a comprehensive approach to sourcing, ensuring that McKesson 3PL can meet a wide array of therapeutic needs. This strategy also mitigates risks associated with dependency on a limited number of products or suppliers.

Seller's Guide — How to Become a Supplier to Mckesson Third Party Logistics

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with McKesson 3PL, especially if they can offer high-quality products that meet FDA standards and demonstrate reliability in supply chain management. Gaps in McK

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Mckesson Third Party Logistics

What products does Mckesson Third Party Logistics import from India?

Mckesson Third Party Logistics imports 2 pharmaceutical products across 2 categories. Top imports: Cefpodoxime ($400.0K), Fluorouracil ($150.0K).

Who supplies pharmaceuticals to Mckesson Third Party Logistics from India?

Mckesson Third Party Logistics sources from 4 verified Indian suppliers. The primary supplier is Ajanta Pharma Limited (63.8% of imports, $5.7M).

What is Mckesson Third Party Logistics's total pharmaceutical import value?

Mckesson Third Party Logistics's total pharmaceutical import value from India is $550.0K, based on 11 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mckesson Third Party Logistics focus on?

Mckesson Third Party Logistics imports across 2 categories. The largest: Advanced Antibiotics (72.7%), Oncology (27.3%).

Get Full Mckesson Third Party Logistics Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.